Gain Therapeutics, Inc. (GANX) 12-Month OLE Shows Stable PD Motor Scores

Gain Therapeutics reported preliminary 12-month open-label extension data for rexaceract with stable MDS-UPDRS Part II+III motor scores in 12 evaluable PD participants and no new safety signals. A Phase 2 protocol is expected to be submitted to the FDA, with trial start planned for 1Q27.Material De…